share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K:外国发行人报告

SEC announcement ·  02/12 16:31
Moomoo AI 已提取核心信息
SciSparc Ltd., a foreign private issuer, reported on February 12, 2024, that it received a termination notice from Dekel Pharmaceuticals Ltd. on February 5, 2024, effectively ending the license agreement between the two companies. The agreement, originally signed on May 20, 2015, and subsequently amended, granted SciSparc an exclusive, worldwide license to certain Dekel technology. Dekel alleges that SciSparc breached material contractual obligations by failing to provide required reports on the licensed products. SciSparc disputes these allegations and plans to defend itself vigorously while assessing the potential impact on its business. The termination and ongoing dispute may have implications for SciSparc's operations and its relationship with Dekel.
SciSparc Ltd., a foreign private issuer, reported on February 12, 2024, that it received a termination notice from Dekel Pharmaceuticals Ltd. on February 5, 2024, effectively ending the license agreement between the two companies. The agreement, originally signed on May 20, 2015, and subsequently amended, granted SciSparc an exclusive, worldwide license to certain Dekel technology. Dekel alleges that SciSparc breached material contractual obligations by failing to provide required reports on the licensed products. SciSparc disputes these allegations and plans to defend itself vigorously while assessing the potential impact on its business. The termination and ongoing dispute may have implications for SciSparc's operations and its relationship with Dekel.
外国私人发行人ScisPARC Ltd. 于2024年2月12日报告称,它于2024年2月5日收到了德克尔制药有限公司的终止通知,实际上终止了两家公司之间的许可协议。该协议最初于2015年5月20日签署,随后进行了修订,授予ScisPARC对某些德克尔技术的全球独家许可。德克尔声称,ScisPARC未能提供有关许可产品的必要报告,从而违反了重要的合同义务。ScisPARC对这些指控提出异议,并计划在评估对其业务的潜在影响时大力为自己辩护。终止和持续的争议可能会对ScisPARC的运营及其与德克尔的关系产生影响。
外国私人发行人ScisPARC Ltd. 于2024年2月12日报告称,它于2024年2月5日收到了德克尔制药有限公司的终止通知,实际上终止了两家公司之间的许可协议。该协议最初于2015年5月20日签署,随后进行了修订,授予ScisPARC对某些德克尔技术的全球独家许可。德克尔声称,ScisPARC未能提供有关许可产品的必要报告,从而违反了重要的合同义务。ScisPARC对这些指控提出异议,并计划在评估对其业务的潜在影响时大力为自己辩护。终止和持续的争议可能会对ScisPARC的运营及其与德克尔的关系产生影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息